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Abstract: Cocoa is a rich source of dietary polyphenols. In vitro as well as cell culture 
data indicate that cocoa polyphenols may exhibit antioxidant and anti-inflammatory, as 
well as anti-atherogenic activity. Several molecular targets (e.g., nuclear factor kappa B, 
endothelial nitric oxide synthase, angiotensin converting enzyme) have been recently 
identified which may partly explain potential beneficial cardiovascular effects of cocoa 
polyphenols. However cocoa polyphenol concentrations, as used in many cell culture 
studies, are not physiologically achievable. Bioavailability studies indicate that plasma 
concentrations of cocoa polyphenols following dietary intake are low and in the nanomolar 
range. Human studies regarding the effect of cocoa polyphenols on vascular health are 
often underpowered and lack a rigorous study design. If dietary cocoa polyphenol intake is 
due to chocolate its high energy content needs to be taken into account. In order to 
determine potential health benefits of cocoa polyphenols large scale, long term, 
randomized, placebo controlled studies, (ideally with a cross-over design) as well as 
prospective studies are warranted. 
Keywords: cocoa; chocolate; polyphenols; cardiovascular disease; endothelial function 
 
 
OPEN ACCESSInt. J. Mol. Sci. 2009, 10                 
 
 
4291
1. Introduction  
 
There is experimental evidence suggesting that cocoa polyphenols may mediate beneficial effects 
on vascular health [1–3]. The present review critically evaluates studies on cocoa polyphenols and 
vascular health as conducted in cultured cells, laboratory rodents and humans over the last decade. 
First bioavailability studies with cocoa polyphenols are summarized. Secondly potential molecular 
targets of cocoa polyphenols are discussed. Thirdly an overview of the human studies on cocoa 
polyphenols and cardiovascular disease prevention is given. Finally merits and limitations of these 
studies are discussed and future challenges in cocoa polyphenol research are presented.  
 
2. Bioavailability of Polyphenols in Cocoa 
 
Cocoa beans (Theobroma cacao) have been used for a long period of time as major ingredient of 
cocoa and chocolate [4,5]. Cocoa is a rich source of polyphenols. Cocoa beans contain approximately 
6-8% polyphenols by dry weight [6]. Polyphenols identified in cocoa beans and cocoa products 
comprise mainly catechins, flavonol glycosides, anthocyanins and procyanidins. As far as procyanidins 
are concerned, up to decamer ones have been identified in cocoa [7]. The chemical structure of 
selected cocoa polyphenols is given in Figure 1.  
The biological activity of cocoa polyphenols largely depend on their bioavailability [8]. The 
bioavailability of cocoa polyphenols has been measured in several studies in humans (Table 1). 
Polyphenols were given as cocoa rich beverages or chocolate. Monomeric flavonoids as well as 
dimeric and trimeric procyanidins have been detected in human plasma after consumption. The peak 
plasma concentration of flavonols was determined 2-3 hours after ingestion [9,10]. Plasma 
concentrations of cocoa polyphenols were often in the nanomolar or low micromolar range. Donovan 
and coworkers demonstrated that commercial chocolate samples available around the world contain a 
predominance of the less bioavailable (-)-catechin enantiomer as compared to the (+)-catechin which is 
present in most other plant derived foods. This may explain the relatively low bioavailability of 
catechins from chocolate and cocoa-containing products [11]. The food matrix seems to be an 
important factor that may affect the bioavailability of cocoa polyphenols. Cocoa powder dissolved in 
milk, as one of the most common ways of cocoa powder consumption, did not change the 
bioavailability of cocoa powder flavonoids in healthy humans [12]. Furthermore, lipid and protein rich 
meals did not affect the bioavailability of cocoa polyphenols. However the uptake of flavonols in 
humans could be increased significantly by concurrent consumption of carbohydrates [13]. 
It is unclear if and to what extend higher oligomeric procyanidins from cocoa are absorbed. 
However, the biological activity of higher procyanidins may be at least partly attributed to their 
colonic breakdown products, including phenolic acids [14]. Data regarding the tissue distribution of 
cocoa polyphenols in laboratory rodents are currently missing. 
Within this review we mainly focus on potential cardiovascular health benefits of cocoa 
polyphenols. However it needs to be taken into account that cocoa beans contain also lipids, sterols, 
minerals and trace elements which may also affect vascular health as reviewed by Steinberg et al. [15].  Int. J. Mol. Sci. 2009, 10                 
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Figure 1. Chemical structure of cocoa polyphenols. 
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Table 1. Human bioavailability studies on cocoa polyphenols. 
No. 
Subjects 
Age  
range 
(mean) 
BMI  
(kg/m²) 
Dietary source of 
polyphenols 
Polyphenol content 
Plasma 
concentration 
Reference 
8 
25–55 
(40 ± 15) 
(± SD) 
23.94 ± 2.35 
(± SD) 
Dark chocolate: 
40 g 
80 g 
Epicatechin: 
82 mg 
164 mg 
Epicatechin: 
0.383 μmol/L (t = 2 h) 
0.7 μmol/L (t = 2.57 h) 
[16] 
20 20–56   
23.8 ± 0.79 
(± SEM) 
Semi-sweet chocolate 
baking bits: 
27 g 
53 g 
80 g 
Total procyanidins 
(epicatechin): 
186 (46) mg 
365 (90) mg 
551 (136) mg 
Epicatechin (t = 2 h): 
0.133 µmol/L 
0.258 µmol/L 
0.355 µmol/L 
[17] 
13 26–49   
23.2 ± 1.2 
(± SEM) 
105 g semi-sweet 
chocolate baking bits 
(of which 80 g 
procyanidin-rich 
chocolate) 
557 mg total 
procyanidins (137 mg 
epicatechin) 
0.257 µmol/L 
epicatechin 
(t = 2 h) 
[10] 
5 
30–33 
(31 ± 1) 
(± SD) 
22.5 ± 1.3 
(± SD) 
96 g chocolate 
66 g cocoa 
Total polyphenols 
(epicatechin): 
2.74 g (760 μmoL) 
2.73 g (760 μmoL) 
Total epicatechin  
(t = 2 h): 
4.77 μmol/L 
4.92 μmol/L 
[18] 
23 
21–62 
 
– 
22 g cocoa powder + 
16 g dark chocolate 
466 mg total 
procyanidins (111 mg 
monomers) 
0.036 nmol/L 
epicatechin 
(t = 2 h) 
[19] 
11 
20–55 
(39 ± 5) 
(± SD) 
24 ± 3 
(± SD) 
37 g high- vs. low-
procyanidin chocolate 
Total procyanidins: 
4 mg/g vs. 0.9 mg/g 
0.212 µmol/L vs. 
0.011 µmol/L 
epicatechin 
(t = 2 h) 
[20] 
16 22–49  – 
300 mL cocoa beverage 
(18.75 g flavanol-rich 
cocoa powder) 
897 mg total epicatechin 
& procyanidins 
1.043 µmol/L 
epicatechin 
(t=2 h) 
[21] 
5 23–34  – 
Cocoa beverage 
(0.375 g cocoa/kg bw)  
Per g cocoa: 
12.2 mg monomers, 
9.7 mg dimers, 
28.2 mg procyanidins 
0.041 µmol/L dimer 
B2, 
5.92 μmol/L 
epicatechin, 
0.16 μmol/L catechin 
(t = 2 h) 
[22] 
6 23–39   
23.1 ± 0.7 
(± SEM) 
400 mL flavanol-rich 
cocoa beverage (37.5 g 
cocoa); 2 days 
Per g cocoa: 
12.2 mg monomers, 
9.7 mg dimers, 
20.2 mg procyanidins 
0.08 μmol/L dimer B2, 
4.11 μmol/L 
epicatechin, 
0.4 μmol/L catechin 
(t = 2 h) 
[23] 
18 –  – 
25 g semi-sweet 
chocolate chips 
220 mg flavanols & 
procyanidins 
0.427 µmol/L 
epicatechin 
(t = 2 h) 
[24] 
32 
31–49 
(40 ± 9) 
(± SD) 
26 ± 4 
(± SD) 
Cocoa flavanol & 
procyanidin 
supplementation for 28 
days 
234 mg/d flavanols & 
procyanidins 
0.116 µmol/L 
epicatechin 
0.091 nmol/L catechin  
(t = 28 d) 
[25] Int. J. Mol. Sci. 2009, 10                 
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3. Putative Health Benefits of Polyphenols from Cocoa and Chocolate 
 
3.1. Studies in Vitro and in Cultured Cells 
 
In vitro studies, as well as studies in cultured cells, have identified several cellular and molecular 
targets by which cocoa polyphenols may mediate beneficial cardiovascular effects (Table 2). In fact it 
has been shown that cocoa polyphenols may prevent and/or inhibit the oxidation of LDL which is a 
key event in atherogenesis [26–30]. Furthermore cocoa polyphenols inhibit lipoxygenase activity in 
vitro [31]. However, comparing the 5-lipoxygenase-inhibitory effect of epicatechin (present in cocoa) 
with those of epigallocatechin-gallate (present in green tea) it was found that the latter flavonoid was 
at least one order of magnitude more potent [32]. There is experimental evidence from studies with rat 
liver microsomes that cocoa polyphenols may decrease NADPH-dependent lipid peroxidation and 
linoleic acid autoxidation [33]. 
 
Table 2. In vitro and cell-culture studies performed with cocoa polyphenols. 
Cell type  Treatment  Outcomes  Reference 
Human LDL 
Cocoa powder extract (5 μmol/L GAE) vs. 
pure catechin (5 μmol/L) 
LDL oxidation ↓ [26] 
Liposomes & human LDL 
Cocoa catechin monomers & procyanidin 
fractions (0.1–10.0 μg/mL) 
LDL oxidation ↓ [27] 
LDL 
220  mL cocoa drink (cocoa concentration: 
1.5, 2.0, 2.5, 3.0, 3.5%) 
LDL oxidation ↓ dose-dependent  [28] 
LDL 
Catechin, epicatechin, procyanidin B2, 
procyanidin C1, cinnamtannin A2 (0.125, 
0.25, 0.5, 1.0, 2.0 μg/mL) 
LDL oxidizability ↓ [29] 
Human LDL & VLDL 
Dark chocolate, cocoa, milk chocolate, hot 
cocoa mixes (126, 224, 52.2, 8.2 μmol/g total 
phenols) 
Lag time of LDL & VLDL oxidation ↑ [30] 
LDL & VLDL 
Dark chocolate & cocoa powder (containing 
fat or defatted) vs. cocoa butter 
LDL & VLDL oxidizability ↓ [49] 
Rat liver microsomes  Cacao liquor 
NADPH-dependent lipid peroxidation ↓ 
Linoleic acid autoxidation ↓ 
[33] 
Recombinant human 5-
LOX 
Cocoa epicatechin & procyanidins 
(10 μmol/L) 
5-LOX activity ↓ 
Proinflammatory mediators (LTB4, 
LTC4, LTD4) ↓ 
[32] 
Isolated rabbit 15-LOX-1 
Cocoa procyanidins (monomers through 
decamers; 2.9 mg/mL) 
15-LOX-1 activity ↓ dose-dependent  [31] 
Recombinant human 
platelet 12-LOX 
Epicatechin & procyanidin decamer  12-LOX activity ↓ dose-dependent   
Human PBMC * 
Cocoa procyanidins (monomers through 
decamers; 25 μg/mL) 
IL-1β secretion ↑ 
IL-2 expression ↓ 
IL-4 expression & secretion ↓ 
[34] 
Human PBMC * 
Cocoa procyanidins (monomers through 
decamers; 25 μg/mL) 
IL-1β transcription & secretion ↑ 
(pentamers-decamers) 
IL-1β transcription & secretion ↓ 
(monomers-tetramers) 
[36] Int. J. Mol. Sci. 2009, 10                 
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Table 2. Cont. 
Human PBMC * 
Cocoa procyanidins (monomers through 
decamers; 25 μg/mL) 
Secretory IL-4 ↑ [35] 
Human PBMC * 
Cocoa procyanidins (monomers through 
decamers; 25 μg/mL) 
TNF-α secretion ↑ [37] 
Human PBMC * 
Cocoa procyanidins (monomers through 
decamers; 25 μg/mL) 
IL-5 secretion ↑ (monomers-trimers) 
IL-5 secretion ↓ (hexamers-decamers) 
[38] 
Human PBMC 
Short- (monomers-pentamers) & long-chain 
(hexamers-decamers) flavanol fractions 
(20 μg/mL) 
Inflammatory mediators (IL-1β, IL-6, IL-
10, TNF-α) ↑ 
[53] 
Whole blood 
Purified trimeric & pentameric cocoa 
procyanidins (3, 10 μmol/L) 
PAC-1 binding & P-selectin expression ↑ 
in unstimulated platelets 
Epinephrine-induced platelet activation ↓ 
[54] 
Isolated rabbit aortic rings  Procyanidin-rich cocoa extracts 
Endothelium-dependent relaxation ↑ 
NOS activity ↑ 
[45] 
ACE from rabbit lung 
Epicatechin, dimeric & hexameric 
procyanidins (0–500 μmol/L) 
ACE activity ↓ molecular weight-
dependent 
[47] 
Murine EL4BOU6 
lymphocytes 
Cocoa extract (5–80  μg/mL total 
polyphenols) vs. epicatechin (60–120 μg/mL 
total polyphenols) 
IL-2 secretion ↓ 
IL-4 secretion ↑ 
T lymphocyte activation ↓ 
[41] 
Murine RAW264.7 
macrophages 
# 
Cocoa extract (5–100  μg/mL total 
polyphenols) vs. epicatechin (60–120 μg/mL 
total polyphenols) 
inducible NO ↓ [42] 
Rat NR8383 macrophages 
# 
Cocoa extract (10–50  μg/mL total 
polyphenols) vs. epicatechin (30–60  μg/mL 
total polyphenols) 
Proinflammatory mediators (TNF-α, 
MCP-1, IL-1α, IL-6) ↓ 
 
Jurkat T cells 
Catechin, epicatechin & B-type oligomers 
(1.7–17.2 μmol/L) 
PMA-induced NF-κB activation ↓ 
IL-2 expression & secretion ↓ 
[55] 
VSMC 
Cocoa procyanidins (0–100  μg/mL) & 
procyanidin B2 (0–100 μmol/L) 
MMP-2 expression & activation ↓ 
VSMC invasion & migration ↓ 
MT1-MMP & MEk1 activities ↓ 
[46] 
HUVEC 
Epicatechin & flavanol metabolites mixture 
vs. control 
Arginase-2 mRNA expression ↓ 
Arginase activity ↓ dose-dependent 
[44] 
GAE gallic acid equivalents, PBMC, peripheral blood mononuclear cells; *, phytohemagglutinin 
(PHA)-stimulated; 
#, lipopolysaccharide (LPS)-stimulated; MCP-1, monocyte chemoattractant 
protein-1;
†, 12-O-tetradecaoylphorbol-13-acetate (TPA)-stimulated; LOX, lipoxygenase; COX-2, 
cyclooxygenase-2; VSMC, vascular smooth muscle cells; MMP, matrix metalloproteinase; MT1, 
membrane type-1; MEK, mitogen-activated protein kinase kinase; HUVEC, human umbilical 
endothelial cells. 
 
Further studies in cultured cells suggest that cocoa polyphenols may exhibit anti-inflammatory 
activity by down regulating the production of pro-inflammatory cytokines including IL1β, IL2, IL4, 
IL6 and TNF-α [34–38]. Activated macrophages can generate large amounts of nitric oxide from   
L-arginine by the action of inducible NO Synthase (iNOS). Overproduction of NO by macrophages has 
been associated with chronic inflammation [39]. The transcription factor NF-B, in cooperation with 
AP-1, cooridnates the expression of iNOS and pro-inflammatory cytokines [40]. Cocoa polyphenols 
may decrease inducible nitric oxide production by inhibiting iNOS gene expression due to NFκB and Int. J. Mol. Sci. 2009, 10                 
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AP1 dependent signal transduction pathways [41,42]. Contrary other studies in cultured RAW264.7 
murine macrophages indicate that oligomeric procyanidins such as procyanidin C2, as present in 
cocoa, exhibit pro-inflammatory activity [43]. Mao et al. have shown that the smaller fraction of cocoa 
polyphenols (monomer-tetramer) consistently decreased IL1β expression in blood mononuclear cells, 
while the larger oligomers (pentamer-decamer) increased its expression [36]. 
Studies in endothelial cells suggest that cocoa polyphenols such as epicatechin inhibit   
arginase-2 mRNA expression and activity levels which in turn may result in a higher availability of the 
vaso-relaxing molecule nitric oxide in the vascular wall [44]. This finding is in line with studies using 
isolated rabbit aortic rings in which endothelium dependent relaxation and an increase in nitric oxide 
synthase has been observed. Karim and co-workers [45] studied the effect of polymeric procyanidins 
on endothelium dependent relaxation (EDR) in aortic rings from New Zealand White rabbits. 
Polymeric procyanidins (tetramers through decamers of catechins) caused EDR in aortic rings. 
Furthermore polymeric procyanidins significantly increased Ca
2+dependent NOS activity whereas 
monomers, dimers and trimers of catechins exhibited no such activity.  
Cocoa procyanidins inhibit metalloproteinase-2 expression and activation in smooth muscle cells 
which may contribute to the anti-atherosclerotic effects of cocoa [46].  
Interestingly cocoa polyphenols have also been shown to inhibit ACE activity [47] which may 
result in a decrease of blood pressure. ACE is centrally involved in the regulation of the rennin-
angiotensin system. Angiotensin causes blood vessels to constrict resulting in increased blood 
pressure. Thus ACE inhibition is a therapeutic approach in blood pressure regulation. As observed for 
the purified ACE enzyme, ACE activity in kidney membrane was inhibited by 100 μmol/L of dimer 
and hexamer epicatechin [47] a concentration which is not physiologically achievable. 
Furthermore cocoa polyphenols circulate as conjugated metabolites whereas in most in vitro studies 
and studies in cultured cells non-conjugated cocoa polyphenols have been used. In this context cell 
culture studies using conjugated cocoa polyphenols are warranted. Furthermore the underlying 
mechanisms involved into the cellular uptake of cocoa polyphenols as well as its cellular 
concentrations and subcellular distribution need to be established. 
 
3.2. Studies in Laboratory Animals 
 
In vitro studies and studies in cultured cells are partly supported by studies in laboratory animals 
indicating that cocoa polyphenols may decrease LDL-oxidation, as well as other biomarkers of lipid 
peroxidation [4]. Furthermore studies in hypercholesterolemic rabbits [48] suggest that cocoa 
polyphenols may prolong LDL-oxidation lag time and decrease area of atherosclerotic lesions in the 
aorta (Table 4). Studies in hamsters report an increase in HDL as well as a decrease in LDL and 
triglyceride levels [49]. Furthermore cocoa procyanidins significantly reduced plasma cholesterol and 
increased steroid excretion in rats fed a high cholesterol diet [50]. In obese diabetic mice and rats a 
decrease in blood glucose as well as a decrease in 8-isoprostane levels has been observed [51]. 
However in other studies in rats no effect of cocoa polyphenols on biomarkers of lipid peroxidation in 
liver and heart has been reported [52]. 
The inhibition of arginase activity has been reported to improve endothelium vasodilating 
relaxation. In this context Schnorr et al.  have found that cocoa flavonols lower vascular arginase Int. J. Mol. Sci. 2009, 10                 
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activity in rat kidney. Arginase competes with endothelial nitric oxide synthase for L-arginine as the 
substrate. Thus an inhibition of arginase activity can be associated with elevated endothelial NO levels 
[44]. Potential mechanisms by which cocoa polyphenols may affect vascular health are summarized in 
Table 3. 
 
Table 3. Potential mechanisms by which polyphenols from cocoa may affect vascular health. 
-  Inhibition of LDL oxidation 
-  Inhibition of lipoxygenase activity 
-  Inhibition of inflammatory gene expression (e.g., IL1β, IL2, IL4, IL6, 
TNFα, iNOS) due to inhibition of NFκB and AP1 transcription factor 
activity 
-  Inhibition of the expression of genes encoding for cell adhesion proteins, 
chemotactic factors and metalloproteinases  
-  Increase in endothelial nitric oxide synthase activity 
-  Inhibition of arginase activity 
-  Inhibition of platelet aggregation 
-  Increase in HDL and decrease in LDL and triglyceride levels 
 
Table 4. In vivo studies with cocoa polyphenols in laboratory animals. 
Species 
No. 
animals 
Experimental 
duration 
(wk) 
Treatment Outcomes  Reference 
Rats 5 – 
Oral administration of 1  g cocoa 
powder/kg bw 
(7.8 mg epicatechin) 
Lipid peroxides in plasma ↓ 
Oxidant-induced α-tocopherol 
consumption ↓ 
[4] 
Rats 5–6 – 
Gastric intubation with 100 mg cocoa 
extract 
Plasma antioxidant capacity ↑ 
Erythrocyte hemolysis ↓ 
[56] 
Rats 48 2 
Diet containing by weight 0.5–2.0% 
flavanol- and procyanidin-rich cocoa 
(12.2 mg/g  epicatechin,  2.8 mg/g 
catechin, 53.3 mg/g procyanidins) 
Oxidative DNA damage in testes ↓ 
No effect on plasma F2-isoprostane 
and TBARS 
[52] 
Hyperchol
esterolemi
c rabbits 
12 24 
Diet containing 10% cocoa powder 
(0.78 g total polyphenols) 
TBARS in plasma↓ 
No effects on plasma cholesterol, 
TG & phospholipids 
LDL oxidation lag time ↑ 
Area of atherosclerotic lesions in 
aorta ↓ 
[48] 
Hamsters  27  10  Brownie (10 g vs. 1 g cocoa powder) 
LDL & TG levels ↓ 
HDL ↑ dose-dependent 
LDL-oxidizability ↓ 
[49] 
Obese-
diabetic 
rats 
40  4  Cocoa extract (600 mg/kg bw/d)  
Blood glucose levels ↓ 
Plasma free fatty acids ↓ 
8-isoprostane levels ↓ 
Superoxide dismutase activity ↑ 
No change in catalase activity 
[51] 
Rats 10 4 
40 g cocoa powder per kg diet 
(11.0 mg/g  epicatechin,  2.8 mg/g 
catechin, 43.0 mg/g procyanidins),  
vs. none  
Renal arginase activity ↓ [44] 
TG, triglycerides, TBARS: Thiobarbituric acid reactive substances. Int. J. Mol. Sci. 2009, 10                 
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3.3. Studies in Humans 
 
There is evidence suggesting that cocoa polyphenols may also positively affect vascular health in 
humans. Several studies in humans suggest that cocoa polyphenols decrease LDL-oxidation 
[19,57,58]. Furthermore, an improvement of plasma antioxidative status due to cocoa polyphenols has 
been shown [9]. Some studies indicate an increase in plasma HDL-cholesterol [19,59,60], a decrease in 
plasma triglyceride and a decrease of biomarkers of lipid peroxidation such as TBARS [17,61] and  
F2-Isoprostanes [62] following cocoa polyphenol consumption.  
Importantly dietary cocoa polyphenols improve endothelial function by increasing vascular-NO-
synthase activity [63–67]. This in turn may lead to a decrease in systolic and diastolic blood pressure 
[68–72]. The magnitude of blood pressure reduction due to cocoa polyphenols is often relatively low 
[73]. Blood pressure lowering effects were more evident in hypertensive than in normotensive 
volunteers [71,73]. However other studies did not report a beneficial effect of cocoa polyphenols on 
blood pressure, and flow mediated dilatation [63]. Balzer et al. [74] studied the effect of flavonol-
containing cocoa on vascular function in medicated diabetic patients in a double-masked, randomized, 
controlled trial. The key observation was an acute effect and a later chronic effect of cocoa flavonols 
on endothelial function as evidenced by improvements in FMD. However, over a 6-week period, 
flavonol-rich cocoa did not modify vascular function in subjects with coronary artery disease. 
Furthermore no differences in soluble cellular adhesion molecule-concentration in plasma and forearm 
blood flow response to ischemia were evident [75]. 
Several studies report anti-aggregatory effects of cocoa polyphenols [25,61]. However the effects of 
cocoa polyphenols on platelet aggregation are rather modest and possibly large amounts need to be 
ingested to exhibit a similar anti-aggregatory effect as reported for aspirin [76]. Nevertheless in a 
recent study by Flammer and coworkers dark chocolate induced coronary vasodilation, improved 
coronary vascular function and decreased platelet adhesion 2 h after consumption of 40 g of dark 
chocolate containing 70% cocoa. These immediate effects were accompanied by a significant increase 
in plasma epicatechin levels [77]. 
Although there is experimental evidence that cocoa polyphenols may act as free radical scavengers 
in vitro, it is unlikely that cocoa polyphenols exhibit significant free radical scavenging activity in 
vivo. Cocoa polyphenols are present at low concentrations in the human plasma and mostly in the 
conjugated form [18]. Conjugation of flavonoids with glucoronic acid and sulphate blocks radical 
scavenging hydroxyl groups [78,79]. Furthermore the free radical scavenging activity of human 
plasma is mainly attributable to vitamin C, vitamin E, bilirubin and urate which occur in many times 
higher concentration as compared to cocoa polyphenols [80]. 
Hypertension is a leading risk of death in the world [87]. If a patient is diagnosed with high blood 
pressure anti-hypertensive drugs need to be prescribed. Functional food and their nutraceuticals may 
have a preventive potential, but they do not play a therapeutic role if the disease has already occurred. 
Although high flavonol cocoa polyphenols improved endothelial function, it did not improve the 
effects of exercise on body fat in obese adults [88]. From a nutritional point of view it is questionable 
whether one should increase the intake of dietary polyphenols due to cocoa-rich products such as 
chocolate, which is rich in fat and sugar and thereby high in energy. In the study by Taubert et al. 
consecutive daily doses of 100 g dark chocolate over two weeks increased the caloric intake by   Int. J. Mol. Sci. 2009, 10                 
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480 kcal per day. Although systolic blood pressure was decreased by 5 mm Hg, in the long run these 
extra calories would probably lead to an increase in body weight and may counteract potential 
beneficial effects on vascular health [89]. Thus products low in sugar and fat should be preferred.  
It needs to be taken into account that many human studies on cocoa polyphenols and vascular health 
as reported in the literature, were not placebo-controlled. Furthermore most studies regarding potential 
health benefits of cocoa polyphenols did include only small number of volunteers as summarized in 
Table 5. In fact many human intervention trials with cocoa polyphenols seem to be underpowered. 
Another problem with these studies is that rigorous study design is missing and compliance of the 
volunteers as well as plasma polyphenol concentrations have often not been reported. In order to 
determine health benefits of cocoa polyphenols large scale, long term randomised placebo-controlled 
studies (ideally with a cross-over design) are warranted [90]. Furthermore prospective studies on cocoa 
polyphenols need to be conducted in the future. 
 
Table 5. Human intervention trials with cocoa and chocolate. 
No. 
Subjects 
Age range 
(mean) 
BMI 
(kg/m²) 
Intervention Polyphenol  content  Outcomes  Reference 
12  39 ± 4.0  –  Cocoa  –  LDL oxidation ↓ [57] 
15  (32.5 ± 6.4)  21.7 ± 2.1 
12 g cocoa powder x3/d 
for 2 weeks, vs. sugar 
2610 mg total polyphenols/d 
(244 mg epicatechin) 
LDL oxidation ↓ 
No change in plasma lipids or 
antioxidants 
Urinary excretion of 
epicatechin/metabolites ↑ 
[58] 
23 
21–62 
(36) 
– 
22 g cocoa powder + 
16 g dark chocolate/d 
for 4 weeks, vs. average 
American diet 
466 mg procyanidins/d 
(111 mg monomers) 
LDL oxidation ↓ 
Serum antioxidant capacity ↑ 
HDL cholesterol ↑ 
[19] 
25 
20–6 
(32.4 ± 7.4) 
24.4 ± 3.4 
37 g dark chocolate & 
31 g cocoa powder in a 
drink/d for 6 weeks, vs. 
none 
651 mg total procyanidins/d 
(chocolate = 168 mg/d, 
cocoa = 483 mg/d) 
LDL oxidizability ↓ 
No effect on inflammation 
markers, or plasma antioxidant 
capacity 
[81] 
45 
19–49 
(26) 
21.5 ± 2.9 / 
24.1 ± 3.5 
75 g dark chocolate or 
high-phenolic dark 
chocolate for 3 weeks, 
vs. 75 g white chocolate 
Total polyphenols 
(epicatechin): 
Dark = 274 (114) mg/d 
High = 418 (170) mg/d 
HDL cholesterol ↑ 
Lipid peroxidation ↓ 
No change in plasma antioxidant 
capacity 
[60] 
25  (38 ± 1)  22.1 ± 0.4 
26 g/d cocoa powder for 
12 weeks 
Per 100 g: 
377 mg epicatechin, 
135 mg catechin, 
158 mg procyanidin B2, 
96.1 mg procyanidin C1 
LDL oxidation ↓ 
HDL-cholesterol ↑ 
[59] 
20  20–56  23.8 ± 0.79 
Semi-sweet chocolate 
baking bits (27, 53, 
80 g), vs. none 
Total procyanidins 
(epicatechin): 
186 (46) mg 
365 (90) mg 
551 (136) mg 
Plasma epicatechin ↑ dose-
dependent 
Antioxidant capacity ↑ 
TBARS ↓ 
[17] 
13  26–49  23.2 ± 1.2 
105 g (of which 80 g 
chocolate) semi-sweet 
baking bits, vs. vanilla 
milk chips 
557 mg total procyanidins 
(137 mg epicatechin) 
Plasma epicatechin ↑ 
Total antioxidant capacity ↑ 
TBARS ↓ 
[10] 
20 20–40  – 
100 ml high- vs. low-
flavanol cocoa drink 
187 mg vs. 14 mg total 
monomers & oligomeric 
procyanidins 
Plasma F2-isoprostanes ↓ [62] Int. J. Mol. Sci. 2009, 10                 
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12 
25–35 
(32.2 ± 1.0) 
21.9 ± 0.4 
100 g dark chocolate 
(with & without 200 mL 
milk), vs. 200 g milk 
chocolate 
Not stated but FRAP values 
(147.4 μmol FE/100 g) 
Plasma antioxidant capacity & 
epicatechin ↑, in absence of milk 
[9] 
30 24–49  – 
Cocoa beverage 
(300 ml, 18.75 g 
procyanidin-rich cocoa 
powder), caffeinated 
beverage, or water 
897 mg total epicatechin & 
oligomeric procyanidins 
Platelet activation & function ↓ [61] 
18 –  – 
25 g semi-sweet 
chocolate chips, vs. 
none 
220 mg flavanols & 
procyanidins 
Plasma epicatechin ↑ 
Platelet function ↓ 
[24] 
32  40 ± 9  26 ± 4 
Cocoa 
flavanol/procyanidin 
tablets for 28 d, vs. 
placebo 
234 mg flavanols & 
procyanidins/d 
Platelet aggregation ↓ 
Plasma ascorbic acid ↑ 
No change in oxidation status 
markers 
Plasma epicatechin & catechin ↑ 
[25] 
30 
20–58 
(30.6) 
– 
Dark (75% cocoa), vs. 
milk (20% cocoa) or 
white (no flavonoids) 
chocolate 
– 
Collagen–induced platelet 
aggregation ↓ 
[82] 
27 
18–72 
(44 ± 3.4) 
26.9 ± 0.9 
High polyphenol vs. low 
flavanol cocoa drink (4x 
230 mL/d for 4 d) 
821 mg/d total flavanols 
(epicatechin, catechin & 
related oligomers) 
Improved peripheral vasodilation  [63] 
20  41 ± 14  25 ± 4 
100 mL high polyphenol 
vs. low flavanol cocoa 
drink 
176 mg total flavanols 
(70 mg monomers, 
106 mg procyanidins) 
NO bioactivity ↑ 
Arterial FMD ↑ 
[64] 
10 –  – 
200 mL high- vs. low-
flavanol cocoa beverage 
985 vs. 80.4 mg total 
flavanols 
Erythrocyte arginase activity ↓ [44] 
13 55–64  21.9  –26.2 
100 g dark chocolate/d 
for 14 d, vs. 90 g white 
chocolate in 
hypertensive subjects 
500 mg/d total polyphenols 
Systolic & diastolic blood 
pressure ↓ 
[72] 
15  (33.9 ± 7.6)  22.6 ± 3.0 
100 g dark chocolate, 
vs. 90 g white chocolate 
for 15 d 
500 mg total polyphenols 
Insulin sensitivity ↑ 
Insulin resistance ↓ 
Systolic blood pressure ↓ 
[70] 
28 –  – 
105 g/d milk chocolate 
for 14 d, vs. cocoa butter 
chocolate; hypertensive 
subjects 
168 mg/d flavanols 
(39 mg monomers, 
126 mg polymers) 
Diastolic & mean blood pressure 
↓ 
LDL cholesterol ↓ 
Oxidative stress markers ↓ 
[69] 
17 
24–32 
(28.9) 
<27.0 
100 g dark chocolate, 
vs. none 
2.62 g procyanidins 
(0.54 g monomers & dimers, 
0.76 g trimer-heptamers) 
Improved endothelial function 
Vasodilation of brachial artery 
No change in blood pressure 
[67] 
20 
(43.65 ± 
7.8) 
25.4 ± 1.7 
100 g/d dark chocolate 
for 15 d, vs. 90 g white 
chocolate in 
hypertensive subjects 
88 mg/d flavanols 
(22 mg catechin, 
66 mg epicatechin) 
Improved insulin sensitivity 
Systolic & diastolic blood 
pressure ↓ 
LDL cholesterol ↓ 
Improved FMD 
[71] 
11  (31 ± 1)  21.8 ± 0.8 
100 mL high- vs. low-
polyphenol cocoa drink 
176–185 mg flavanols 
(70–74 mg monomers, 
20–22 mg epicatechin, 
106–111 mg procyanidins) 
Circulating NO & FMD ↑ [65] 
16 25–32  19–23 
300 mL high- vs. low-
flavanol cocoa drink 
917 mg flavanols 
(19% epicatechin) 
Circulating NO species ↑ 
FMD response of conduit arteries 
↑ 
Microcirculation ↑ 
[66] 
20 –  – 
40 g dark chocolate, vs. 
white chocolate 
Same brand as used for 
Vlachopoulos et al. (2005) 
Improved FMD 
Platelet function ↓ 
Plasma total antioxidant status ↑ 
[83] Int. J. Mol. Sci. 2009, 10                 
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34 
18–74 
(47.9 ± 3.0) 
28.0 ± 1.9/ 
28.4 ± 1.3 
High polyphenol cocoa 
drink 4x 230 mL/d for 
4–6 d, vs. none 
Per 100 mL: 
9.2 mg epicatechin, 
10.7 mg catechin, 
69.3 mg flavanol oligomers 
(821 mg/d) 
NO synthesis ↓ 
FMD ↑ 
Pulse wave amplitude ↑ 
[84] 
40  61 ± 9  27.1 ± 3.9 
48 g flavanol-rich 
chocolate bar + 18 g 
cocoa beverage/d, 
vs. placebo for 6 weeks 
in subjects with 
coronary artery disease 
444 vs. 19.6 mg/d total 
flavanols 
(107 vs. 4.7 mg epicatechin) 
No acute or chronic changes in 
FMD, systemic arterial 
compliance, forearm blood flow, 
soluble cellular adhesion 
molecules 
[75] 
32 
57.7 ± 2.2/ 
55.4 ± 1.7 
24.9 ± 1.0/ 
25.3 ± 0.8 
High- vs. low-flavanol 
cocoa beverage for 
6 weeks in 
hypercholesterolemic 
subjects 
446 vs. 43 mg total 
flavanols 
FMD ↑ 
Brachial artery hyperaemic blood 
flow ↑ 
VCAM-1 ↓ 
[85] 
11 
22–32 
(27 ± 1) 
22 ± 1 
100 mL high-flavanol 
vs. low-phenolic cocoa 
drink x3/d for 1 week 
Per 100 ml: 
59 mg epicatechin, 
15 mg catechin, 
232 mg flavanol oligomers 
(918 mg/d procyanidins) 
FMD ↑ 
No change in biomarkers of 
oxidative stress 
[86] 
45 
30–75 
(52.8 ± 
11.0) 
30.1 ± 3.3 
74 g solid dark 
chocolate 
(22 g cocoa powder); 
240 ml liquid cocoa 
(sugar-free vs. sugared) 
821 mg total flavanols; 
805.2 & 8.5 mg total 
flavanols 
Improved FMD 
Systolic & diastolic blood 
pressure ↓ 
[68] 
FE: Ferric equivalents; FMD: Flow-mediated dilation; FRAP: Ferric-reducing ability of plasma; 
TBARS: Thiobarbituric acid reactive substances. 
All data refer to healthy subjects unless otherwise stated.  
 
4. Conclusions 
 
There is epidemiological evidence suggesting that consumption of fruits and vegetables appear to 
have a protective effect against coronary heart disease [91]. Furthermore, the intake of certain 
flavonoid rich food items may be inversely related to coronary heart disease [92,93]. However, only 
few epidemiological data are currently available for cocoa polyphenols. In a cohort of elderly men, 
cocoa intake was inversely associated with blood pressure and 15-year cardiovascular and all-cause 
mortality [94]. It is suggested that before drawing conclusions, confirmation by further observational 
and experimental studies on cocoa polyphenols is needed. Mink et al. [95] studied flavonoid intake 
and cardiovascular disease mortality in a prospective study in postmenopausal women. Individual 
foods associated with a reduction of cardiovascular disease risk included bran, apples and pears, red 
wine, grapefruit, strawberries and chocolate. 
Hooper and coworkers have recently conducted a meta-analysis on flavonoids, flavonoid-rich foods 
and cardiovascular disease risk. One hundred thirty-three trials were included into this meta-analysis. 
Importantly chocolate increased FMD and reduced both systolic and diastolic blood pressure [96]. 
Janszky et al. [97] assessed the long-term effects of chocolate consumption amongst patients with 
established coronary heart disease in a population based cohort study comprising >1100 non diabetic 
patients. Chocolate consumption was associated with a significantly reduced cardiac mortality in 
patients surviving the first acute myocardial infarction. 
In a recent review it has been stated that most cocoa polyphenol studies in humans over the last 
decade have been mainly funded by industrial sponsors. Thus there may be potential for research bias Int. J. Mol. Sci. 2009, 10                 
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[98]. Nevertheless several studies consistently reported beneficial effects of dietary polyphenols from 
cocoa on vascular health. However, it should be considered that the products used in controlled studies 
often contain much higher polyphenol contents than most of the commercially available products 
[94,99]. Since flavonols exhibit a bitter taste manufacturers have established processing techniques for 
cocoa which eliminate the bitterness together with the flavonoides [100]. As much as 90% of the 
flavonoids may be lost due cocoa processing [76].Thus, it needs to be established whether the 
consumption of products with a lower polyphenol content are associated with any health benefits in 
humans. Furthermore the food industry is encouraged to label the flavonoid content on their cocoa 
derived products. 
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